Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > NexImmune Appoints Kenneth Carter, PhD, as President and CEO and Jonathan Schneck, MD, PhD as Chairman of Clinical and Scientific Advisory Board: Licenses Technology From The Johns Hopkins University

Abstract:
NexImmune, an early stage biopharmaceutical company, announced today the appointment of Kenneth Carter, PhD, as the company's President and Chief Executive Officer, and Professor Jonathan Schneck, MD, PhD, as Chairman of the company's Clinical and Scientific Advisory Board. At the same time, NexImmune announced that the company has licensed the Artificial IMmune (AIM™) nanotechnology for immuno-therapy, developed by Dr. Mathias Oelke and Dr. Schneck's laboratory from The Johns Hopkins University.

NexImmune Appoints Kenneth Carter, PhD, as President and CEO and Jonathan Schneck, MD, PhD as Chairman of Clinical and Scientific Advisory Board: Licenses Technology From The Johns Hopkins University

Gaithersburg, MD | Posted on January 4th, 2012

Prior to NexImmune, Dr. Carter was the President, CEO and a co-founder of Noble Life Sciences. Dr. Carter has also played a key leadership role in launching several other biotechnology companies including Avalon Pharmaceuticals, Inc. where he served as CEO for 10 years until 2009 when Avalon merged with Clinical Data, Inc. During his tenure at Avalon, the company developed a unique biomarker-based drug discovery and development engine; completed an IPO and listing on the NASDAQ market; established drug discovery programs in colon, breast, pancreatic and hematological cancers; and established partnerships with Merck, Novartis, Sanofi-Aventis, and AstraZeneca/MedImmune. Prior to Avalon, Dr. Carter directed the gene mapping initiative at Human Genome Sciences, Inc. where he played a lead role in the discovery, cloning, and chromosomal mapping of dozens of novel human genes. Dr. Carter serves on the Advisory Council for the Center for Biotechnology Education at The Johns Hopkins University where he also holds an adjunct faculty appointment.

"The AIM technology provides an exciting leap in immuno-therapy for a variety of cancer and other diseases whereby artificial cells direct specific immune responses against a specific disease. I am very pleased to lead the team that will commercialize this exciting new technology. Our first development target will be a therapeutic to treat melanoma," said Dr. Carter.

Dr. Schneck is Professor of Pathology, Medicine and Oncology at Johns Hopkins School of Medicine. He is well known for several key scientific contributions to the field including extensive work in the artificial manipulation of immune system components in order to maximize T cell responses. To facilitate the study of both normal and aberrant immune responses, he and his laboratory have developed a variety of innovative nano-molecular tools including the DimerX technology, for analysis of antigen-specific T cells, marketed by BD Biosciences, and artificial Antigen Presenting Cell (aAPC), the foundation of the AIM technology. The quality and potential of Dr. Schneck's scientific work has been well recognized with excellent support from granting agencies including Dr. Schneck leading a team of investigators that were awarded a $12 million grant in 2009, the largest basic science immunology grant in the history of Johns Hopkins University. Dr. Schneck has more than 200 scientific publications and is an inventor on several dozen submitted and granted patents.

"It is terrific to work with Ken and his team on the commercial transformation of the AIM technology to a product development platform. If the products to be developed by NexImmune are successful in human clinical trials, I believe the AIM technology has the potential to provide a major step forward for immuno-therapy for a variety of diseases," said Dr. Schneck.

####

About NexImmune, Inc.
NexImmune is an early stage biopharmaceutical company developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIM™) nanotechnology platform. Central to the AIM™ technology are artificial Antigen Presenting Cells (aAPCs) that can be engineered to orchestrate a highly specific immune attack directed toward any foreign substance or cell type in the body. In pre-clinical studies, aAPCs have been shown to have potential utility as vaccines and therapeutic agents and can also be used for the development of diagnostic products. NexImmune is using the AIM technology platform to develop a pipeline of products to treat cancer. The company's first therapeutic will be targeted at the treatment of advanced stage melanoma.

For more information, please click here

Contacts:
NexImmune, Inc.
22 Firstfield Road
Suite 280
Gaithersburg, MD 20878
phone: 301-685-1688
website www.neximmune.com

Media Contact Information:
Faye Coggins
301-685-1688 ext.104

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers develop artificial building blocks of life March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Patents/IP/Tech Transfer/Licensing

Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment: In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cance May 13th, 2022

Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

Appointments/Promotions/New hires/Resignations/Deaths

The National Space Society Mourns the Passing of Robert Krone, Founder of the Kepler Space Institute: Krone's Visionary and Humanistic Approach to the Study of Space Communities and Settlement Was Unique September 22nd, 2021

Leibniz Prize winner Professor Dr. Oliver G. Schmidt moves to Chemnitz University of Technology: President Professor Dr. Gerd Strohmeier refers to an 'absolute top transfer' September 10th, 2021

JEOL USA Welcomes New Managing Director, Hidetaka Sawada April 19th, 2021

The National Space Society Remembers Ben Bova : NSS Mourns the Loss of a Visionary NSS Leader December 2nd, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project